Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1999 May;8(3):263-8.
doi: 10.1023/a:1008859420641.

Quality of life assessment in adults with type 1 Gaucher disease

B J Masek  1 , K B Sims, C M Bove, M S Korson, P Short, D K Norman
Affiliations
Clinical Trial

Quality of life assessment in adults with type 1 Gaucher disease

B J Masek et al. Qual Life Res. 1999 May.

Abstract

The effect of enzyme replacement therapy on health-related quality of life in 25 adults with type 1 Gaucher disease was investigated over a 2-year period. Quality of life was assessed using the SF-36 Health Survey (SF-36). Psychological functioning was assessed using the Symptom Checklist--90R. The results indicated significant improvement in 7 of 8 SF scale scores beginning at 18 months of therapy (P < 0.05 to 0.001). The SF scale showing improvement first was Vitality (energy level and fatigue) at 6 months of therapy (P < 0.01). The SF-36 scales showing the largest improvements were Role-Physical and Social Functioning (P < 0.001). Compared to the general US adult population, the study population's health profile was significantly lower prior to starting therapy but by 24 months of therapy there were no differences between the two. No differences were found in psychological functioning compared to a US adult normative group at the start of therapy. However, within the study population there was significant improvement in mood and global functioning and fewer psychological symptoms reported at 24 months of therapy. The findings indicate that enzyme replacement therapy for type 1 Gaucher disease has a positive impact on health-related quality of life from the patient's perspective.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ann Intern Med. 1993 Apr 15;118(8):622-9 - PubMed
    1. N Engl J Med. 1992 Dec 3;327(23 ):1676-8 - PubMed
    1. J Bone Miner Res. 1996 Nov;11(11):1801-7 - PubMed
    1. Psychother Psychosom. 1993;59(1):1-10 - PubMed
    1. Qual Life Res. 1993 Aug;2(4):297-303 - PubMed

Publication types